Pharma

Investigations probe serious movement/cognitive side effects and clusters of allergic reactions tied to specific batches; recalls and monitoring advised for affected immunoglobulin products.

Randomized, placebo-controlled Phase III will enroll ~1,800 symptomatic COPD adults (≥40) with blood eosinophils <300 cells/µL to test exacerbation reduction over 52–76 weeks.

Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.

Revenue +8.4% AER; core operating profit +11.2% AER; ORZEYFUL approved in US/Japan/China; MIMRYLO launched in US; zasocitinib accepted for FDA Priority Review; FY outlook raised for FX.

Signed a Sept 25, 2026 agreement to join a global CDMO alliance for cell and gene therapy, aiming to expand manufacturing support, quality tools and cross-region collaboration.

Links Mitsui's materials and InnoCell plates with an AI-driven closed-loop platform to improve uniformity and manufacture of human cells and organoids for drug discovery and regenerative medicine.

Achieved a 55% rise in circularity intensity at Andalusian sites; partnerships converted spent catalysts into mortar and the firm advances water and biodiversity commitments.

At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.

First interim IDMC readout from LiGeR‑HN1 shows a 50% reduction in risk of death and a >3‑fold increase in objective response for the combination versus pembrolizumab alone.

Specialty Medicines and new launches drove mid-single‑digit sales growth and core profit expansion, while a £328m restructuring charge cut total operating profit and EPS.